{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:11:54Z","timestamp":1790424714644,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA098472"],"award-info":[{"award-number":["R01CA098472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA178393"],"award-info":[{"award-number":["R01CA178393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41375-018-0290-y","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:07:22Z","timestamp":1540282042000},"page":"1243-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective \u03b3-chain cytokines, decreases leukemic T-cell viability"],"prefix":"10.1038","volume":"33","author":[{"given":"T. Tiffany","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cait E.","family":"Hamele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Dighe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Feith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"290_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595\u2013601.","journal-title":"Nat Rev Immunol"},{"key":"290_CR2","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/S0021-9258(18)49895-X","volume":"266","author":"TA Waldmann","year":"1991","unstructured":"Waldmann TA. The interleukin-2 receptor. J Biol Chem. 1991;266:2681\u20134.","journal-title":"J Biol Chem"},{"key":"290_CR3","doi-asserted-by":"publisher","first-page":"22338","DOI":"10.1074\/jbc.M115.661074","volume":"290","author":"T Nata","year":"2015","unstructured":"Nata T, Basheer A, Cocchi F, Besien R, van, Massoud R, Jacobson S, et al. Targeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum. J Biol Chem. 2015;290:22338\u201351.","journal-title":"J Biol Chem"},{"key":"290_CR4","doi-asserted-by":"crossref","unstructured":"Yamagishi M, Watanabe T Molecular Hallmarks of Adult T Cell Leukemia. Front Microbiol [Internet]. 2012 Sep 17 [cited 2017 Sep 12];3. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3444139\/","DOI":"10.3389\/fmicb.2012.00334"},{"issue":"34 suppl","key":"290_CR5","doi-asserted-by":"publisher","first-page":"24s","DOI":"10.1183\/09031936.01.00229601","volume":"18","author":"JC Kips","year":"2001","unstructured":"Kips JC. Cytokines in asthma. Eur Respir J. 2001;18(34 suppl):24s\u201333s.","journal-title":"Eur Respir J"},{"key":"290_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0046-8177(96)90408-6","volume":"27","author":"MA Wasik","year":"1996","unstructured":"Wasik MA, Sackstein R, Novick D, Butmarc JR, Zhang Q, Vonderheid EC, et al. Cutaneous CD56+large T-cell lymphoma associated with high serum concentration of IL-2. Hum Pathol. 1996;27:738\u201344.","journal-title":"Hum Pathol"},{"key":"290_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/0008-5472.CAN-07-2403","volume":"68","author":"M Marzec","year":"2008","unstructured":"Marzec M, Halasa K, Kasprzycka M, Wysocka M, Liu X, Tobias JW, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+cutaneous T-cell lymphoma cells. Cancer Res. 2008;68:1083\u201391.","journal-title":"Cancer Res"},{"key":"290_CR8","doi-asserted-by":"crossref","unstructured":"Ribeiro ST, Ribot JC, Silva-Santos B. Five Layers of Receptor Signaling in \u03b3\u03b4 T-Cell Differentiation and Activation. Front Immunol [Internet]. 2015 Jan 26 [cited 2018 Mar23];6. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4306313\/","DOI":"10.3389\/fimmu.2015.00015"},{"key":"290_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.59566\/IJBS.2011.7181","volume":"7","author":"M Ito","year":"2011","unstructured":"Ito M, Zhao N, Zeng Z, Zhou X, Chang C-C, Zu Y. Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1\/2 Activation. Int J Biomed Sci Ijbs. 2011;7:181\u201390.","journal-title":"Int J Biomed Sci Ijbs"},{"key":"290_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ccr.2012.09.009","volume":"22","author":"A Mishra","year":"2012","unstructured":"Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012;22:645\u201355.","journal-title":"Cancer Cell"},{"key":"290_CR11","doi-asserted-by":"crossref","unstructured":"Tabb\u00f3 F, Barreca A, Piva R, Inghirami G. ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol [Internet]. 2012 May 11 [cited 2018 Mar22];2. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3355932\/","DOI":"10.3389\/fonc.2012.00041"},{"key":"290_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/jid.2011.27","volume":"131","author":"T Krejsgaard","year":"2011","unstructured":"Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat3 signaling pathway. J Invest Dermatol. 2011;131:1331\u20138.","journal-title":"J Invest Dermatol"},{"key":"290_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/cncr.10480","volume":"96","author":"L Dahmoush","year":"2002","unstructured":"Dahmoush L, Hijazi Y, Barnes E, Stetler-Stevenson M, Abati A. Adult T-cell leukemia\/lymphoma. Cancer Cytopathol. 2002;96:110\u20136.","journal-title":"Cancer Cytopathol"},{"key":"290_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1172\/JCI41344","volume":"120","author":"G Malamut","year":"2010","unstructured":"Malamut G, El Machhour R, Montcuquet N, Martin-Lanner\u00e9e S, Dusanter-Fourt I, Verkarre V, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest. 2010;120:2131\u201343.","journal-title":"J Clin Invest"},{"key":"290_CR15","doi-asserted-by":"publisher","first-page":"S244","DOI":"10.3816\/CLM.2009.s.019","volume":"9","author":"MV Shah","year":"2009","unstructured":"Shah MV, Zhang R, Loughran TP. Never say die: survival signaling in large granular lymphocyte leukemia. Clin Lymphoma Myeloma. 2009;9:S244\u201353.","journal-title":"Clin Lymphoma Myeloma"},{"key":"290_CR16","first-page":"652","volume":"2012","author":"D Zhang","year":"2012","unstructured":"Zhang D, Loughran TP. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. ASH Educ Program Book. 2012;2012:652\u20139.","journal-title":"ASH Educ Program Book"},{"key":"290_CR17","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","volume":"117","author":"T Lamy","year":"2011","unstructured":"Lamy T, Loughran TP. How I treat LGL leukemia. Blood. 2011;117:2764\u201374.","journal-title":"Blood"},{"key":"290_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.blre.2014.02.001","volume":"28","author":"SN Steinway","year":"2014","unstructured":"Steinway SN, Leblanc F, Loughran TP. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014;28:87\u201394.","journal-title":"Blood Rev"},{"key":"290_CR19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HLM Koskela","year":"2012","unstructured":"Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanm\u00e4ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905\u201313.","journal-title":"N Engl J Med"},{"key":"290_CR20","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, Ng KP, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120:3048\u201357.","journal-title":"Blood"},{"key":"290_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/leu.2015.263","volume":"30","author":"E Andersson","year":"2016","unstructured":"Andersson E, Kuusanm\u00e4ki H, Bortoluzzi S, Lagstr\u00f6m S, Parsons A, Rajala H, et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia. 2016;30:1204\u20138.","journal-title":"Leukemia"},{"key":"290_CR22","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","volume":"121","author":"HLM Rajala","year":"2013","unstructured":"Rajala HLM, Eldfors S, Kuusanm\u00e4ki H, Adrichem AJ, van, Olson T, Lagstr\u00f6m S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013;121:4541\u201350.","journal-title":"Blood"},{"key":"290_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2001","unstructured":"Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351\u201362.","journal-title":"J Clin Invest"},{"key":"290_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/07853890.2014.882105","volume":"46","author":"HLM Rajala","year":"2014","unstructured":"Rajala HLM, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med. 2014;46:114\u201322.","journal-title":"Ann Med"},{"key":"290_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7025","volume":"6","author":"C K\u00fc\u00e7\u00fck","year":"2015","unstructured":"K\u00fc\u00e7\u00fck C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells. Nat Commun. 2015;6:6025.","journal-title":"Nat Commun"},{"key":"290_CR26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V89.1.201","volume":"89","author":"R Zambello","year":"1997","unstructured":"Zambello R, Facco M, Trentin L, Sancetta R, Tassinari C, Perin A, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997;89:201\u201311.","journal-title":"Blood"},{"key":"290_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2011-04-346759","volume":"119","author":"J Chen","year":"2012","unstructured":"Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, et al. Increased serum soluble IL-15R\u03b1 levels in T-cell large granular lymphocyte leukemia. Blood. 2012;119:137\u201343.","journal-title":"Blood"},{"key":"290_CR28","doi-asserted-by":"publisher","first-page":"16308","DOI":"10.1073\/pnas.0806447105","volume":"105","author":"R Zhang","year":"2008","unstructured":"Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci Usa. 2008;105:16308\u201313.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"290_CR29","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1182\/blood-2010-04-277418","volume":"116","author":"J Chen","year":"2010","unstructured":"Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, Bamford R, et al. Autocrine\/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood. 2010;116:5948\u201356.","journal-title":"Blood"},{"key":"290_CR30","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1073\/pnas.87.13.5218","volume":"87","author":"CL Tendler","year":"1990","unstructured":"Tendler CL, Greenberg SJ, Blattner WA, Manns A, Murphy E, Fleisher T, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci Usa. 1990;87:5218\u201322.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"290_CR31","first-page":"2602","volume":"166","author":"JM Mariner","year":"2001","unstructured":"Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol Balt 1950. 2001;166:2602\u20139.","journal-title":"J Immunol Balt 1950"},{"key":"290_CR32","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood-2010-09-305425","volume":"117","author":"W Ju","year":"2011","unstructured":"Ju W, Zhang M, Jiang J, Thomas CJ, Oh U, Bryant BR, et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM\/TSP. Blood. 2011;117:1938\u201346.","journal-title":"Blood"},{"key":"290_CR33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","volume":"82","author":"TA Waldmann","year":"1993","unstructured":"Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701\u201312.","journal-title":"Blood"},{"key":"290_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","volume":"121","author":"TA Waldmann","year":"2013","unstructured":"Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood. 2013;121:476\u201384.","journal-title":"Blood"},{"key":"290_CR35","doi-asserted-by":"publisher","first-page":"14169","DOI":"10.1073\/pnas.2335979100","volume":"100","author":"S Dubois","year":"2003","unstructured":"Dubois S, Shou W, Haneline LS, Fleischer S, Waldmann TA, M\u00fcller JR. Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. Proc Natl Acad Sci Usa. 2003;100:14169\u201374.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"290_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","volume":"155","author":"JL Berkowitz","year":"2014","unstructured":"Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma. Clin Immunol Orlando Fla. 2014;155:176\u201387.","journal-title":"Clin Immunol Orlando Fla"},{"key":"290_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mce.2017.02.019","volume":"451","author":"TA Waldmann","year":"2017","unstructured":"Waldmann TA. JAK\/STAT pathway directed therapy of T-cell leukemia\/lymphoma: Inspired by functional and structural genomics. Mol Cell Endocrinol. 2017;451:66\u201370.","journal-title":"Mol Cell Endocrinol"},{"key":"290_CR38","doi-asserted-by":"publisher","first-page":"11030","DOI":"10.1073\/pnas.1412626112","volume":"112","author":"R Massoud","year":"2015","unstructured":"Massoud R, Enose-Akahata Y, Tagaya Y, Azimi N, Basheer A, Jacobson S. Common \u03b3-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy\/tropical spastic paraparesis. Proc Natl Acad Sci. 2015;112:11030\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"Suppl 1","key":"290_CR39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood.V130.Suppl_1.695.695","volume":"130","author":"P Frohna","year":"2017","unstructured":"Frohna P, Tagaya Y, Ratnayake A, Doerr N, Basheer A, Al-Mawsawi L, et al. Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL-9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+Central Memory T-Cells. Blood. 2017;130(Suppl 1):695\u2013695.","journal-title":"Blood"},{"key":"290_CR40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.leukres.2013.10.002","volume":"37","author":"T Ren","year":"2013","unstructured":"Ren T, Yang J, Broeg K, Liu X, Loughran TP Jr., Cheng H. Developing an in vitro model of T cell type of large granular lymphocyte leukemia. Leuk Res. 2013;37:1737\u201343.","journal-title":"Leuk Res"},{"key":"290_CR41","first-page":"406","volume":"24","author":"MJ Robertson","year":"1996","unstructured":"Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996;24:406\u201315.","journal-title":"Exp Hematol"},{"key":"290_CR42","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1073\/pnas.89.7.2789","volume":"89","author":"H Otani","year":"1992","unstructured":"Otani H, Siegel JP, Erdos M, Gnarra JR, Toledano MB, Sharon M, et al. Interleukin (IL)-2 and IL-3 induce distinct but overlapping responses in murine IL-3-dependent 32D cells transduced with human IL-2 receptor beta chain: involvement of tyrosine kinase(s) other than p56lck. Proc Natl Acad Sci Usa. 1992;89:2789\u201393.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"290_CR43","first-page":"2169","volume":"162","author":"M Maeda","year":"1985","unstructured":"Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Anal T Cell Recept gene Rearrange J Exp Med. 1985;162:2169\u201374.","journal-title":"Anal T Cell Recept gene Rearrange J Exp Med"},{"key":"290_CR44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/15384047.2016.1235669","volume":"18","author":"KC Olson","year":"2017","unstructured":"Olson KC, Kulling PM, Olson TL, Tan S-F, Rainbow RJ, Feith DJ, et al. Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. Cancer Biol Ther. 2017;18:290\u2013303.","journal-title":"Cancer Biol Ther"},{"key":"290_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V96.1.275","volume":"96","author":"C Nicot","year":"2000","unstructured":"Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 2000;96:275\u201381.","journal-title":"Blood"},{"key":"290_CR46","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.1516208112","volume":"112","author":"M Zhang","year":"2015","unstructured":"Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, et al. Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2\u2013dependent adult T-cell leukemia. Proc Natl Acad Sci Usa. 2015;112:12480\u20135.","journal-title":"Proc Natl Acad Sci Usa"},{"key":"290_CR47","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1182\/blood-2010-09-307504","volume":"117","author":"N Sato","year":"2011","unstructured":"Sato N, Sabzevari H, Fu S, Ju W, Petrus MN, Bamford RN, et al. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15R\u03b1. Blood. 2011;117:4032\u201340.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0290-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0290-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T17:34:22Z","timestamp":1720719262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0290-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0290-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Nazli Azimi and Yutaka Tagaya are employed by BIONIZ Therapeutics, the producer of BNZ-1. Thomas Loughran, Jr. and Thomas Waldmann are on the scientific advisory board of BIONIZ Therapeutics. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}